ESR1 and breast carcinoma: The results reported by Sisci et al. suggest that the role of FOXO3 in breast cancer is linked to the oestrogen receptor α (ERα) status: in ERα-positive cells, FOXO3 inhibits breast carcinogenesis, while in ERα-negative cells, FOXO3 tend to promote breast carcinogenesis [15].